Cargando…

Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes

BACKGROUND: The authors evaluated mocetinostat (a class I/IV histone deacetylase inhibitor) in patients with urothelial carcinoma harboring inactivating mutations or deletions in CREB binding protein [CREBBP] and/or E1A binding protein p300 [EP300] histone acetyltransferase genes in a single‐arm, op...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grivas, Petros, Mortazavi, Amir, Picus, Joel, Hahn, Noah M., Milowsky, Matthew I., Hart, Lowell L., Alva, Ajjai, Bellmunt, Joaquim, Pal, Sumanta K., Bambury, Richard M., O’Donnell, Peter H., Gupta, Sumati, Guancial, Elizabeth A., Sonpavde, Guru P., Faltaos, Demiana, Potvin, Diane, Christensen, James G., Chao, Richard C., Rosenberg, Jonathan E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590473/ https://www.ncbi.nlm.nih.gov/pubmed/30570744 http://dx.doi.org/10.1002/cncr.31817

Ejemplares similares

Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2)
por: Rosenberg, Jonathan E., et al.
Publicado: (2018)

Mocetinostat combined with gemcitabine for the treatment of leiomyosarcoma: Preclinical correlates
por: Lopez, Gonzalo, et al.
Publicado: (2017)

Epigenetics in Prostate Cancer
por: Albany, Costantine, et al.
Publicado: (2011)

A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer
por: Zhang, Tian, et al.
Publicado: (2020)

Mocetinostat activates Krüppel-like factor 4 and protects against tissue destruction and inflammation in osteoarthritis
por: Kawata, Manabu, et al.
Publicado: (2023)

Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma
por: Kamat, Ashish M., et al.
Publicado: (2017)

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma
por: Kamat, Ashish M., et al.
Publicado: (2017)

ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat
por: Meidhof, Simone, et al.
Publicado: (2015)

Prostate-Specific Membrane Antigen Targeted Polymersomes for Delivering Mocetinostat and Docetaxel to Prostate Cancer Cell Spheroids
por: Karandish, Fataneh, et al.
Publicado: (2016)

HDAC class I inhibitor, Mocetinostat, reverses cardiac fibrosis in heart failure and diminishes CD90+ cardiac myofibroblast activation
por: Nural-Guvener, Hikmet F, et al.
Publicado: (2014)

Anti-Fibrotic Effects of Class I HDAC Inhibitor, Mocetinostat Is Associated with IL-6/Stat3 Signaling in Ischemic Heart Failure
por: Nural-Guvener, Hikmet, et al.
Publicado: (2015)

Class I HDAC inhibitor mocetinostat induces apoptosis by activation of miR-31 expression and suppression of E2F6
por: Zhang, Q, et al.
Publicado: (2016)

In vitro anti-proliferative effect of capecitabine (Xeloda) combined with mocetinostat (MGCD0103) in 4T1 breast cancer cell line by immunoblotting
por: Kaya Çakir, Hacer, et al.
Publicado: (2021)

HER2 as a target in invasive urothelial carcinoma
por: Bellmunt, Joaquim, et al.
Publicado: (2015)

Circulating Biomarkers in Bladder Cancer
por: Nandagopal, Lakshminarayanan, et al.
Publicado: (2016)

Utility of cell-free nucleic acid and circulating tumor cell analyses in prostate cancer
por: Gourdin, Theodore, et al.
Publicado: (2018)

Molecularly Targeted Therapy towards Genetic Alterations in Advanced Bladder Cancer
por: Thomas, Jonathan, et al.
Publicado: (2022)

Atezolizumab in patients with renal insufficiency and mixed variant histology: analyses from an expanded access program in platinum-treated locally advanced or metastatic urothelial carcinoma
por: Hoffman-Censits, Jean, et al.
Publicado: (2020)

Emerging Therapies in Penile Cancer
por: Alencar, Antonio Machado, et al.
Publicado: (2022)

Gene expression in primary and metastatic kidney cancer to discover drivers of metastasis and targets for drug development
por: Zhao, Amy, et al.
Publicado: (2015)

SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy
por: Choy, Edwin, et al.
Publicado: (2018)

Real-World Effectiveness of Chemotherapy in Elderly Patients With Metastatic Bladder Cancer in the United States
por: Galsky, Matthew D., et al.
Publicado: (2018)

Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy
por: Bellmunt, Joaquim, et al.
Publicado: (2016)

Corrigendum to “SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy”
por: Choy, Edwin, et al.
Publicado: (2019)

Case report: Immune-mediated meibomian gland dysfunction following pembrolizumab therapy for advanced urothelial carcinoma
por: Nguyen, Charles B., et al.
Publicado: (2022)

Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival
por: Ramos, Jorge D., et al.
Publicado: (2016)

New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib
por: Cowey, C Lance, et al.
Publicado: (2010)

Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Lohiya, Vipin, et al.
Publicado: (2016)

Stem-Like Signature Predicting Disease Progression in Early Stage Bladder Cancer. The Role of E2F3 and SOX4
por: Bellmunt, Joaquim
Publicado: (2018)

Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database
por: Del Bene, Gabriella, et al.
Publicado: (2018)

Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status
por: Grivas, Petros, et al.
Publicado: (2020)

Polymorphism of human acetyltransferases.
por: Meyer, U A
Publicado: (1994)

Acetyltransferases and tumour suppression
por: Phillips, A C, et al.
Publicado: (2000)

Profile of Class I Histone Deacetylases (HDAC) by Human Dendritic Cells after Alcohol Consumption and In Vitro Alcohol Treatment and Their Implication in Oxidative Stress: Role of HDAC Inhibitors Trichostatin A and Mocetinostat
por: Agudelo, Marisela, et al.
Publicado: (2016)

Urothelial Cancer With Occult Bone Marrow Metastases and Isolated Thrombocytopenia
por: Alva, Ajjai, et al.
Publicado: (2015)

Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy
por: Rose, Tracy L., et al.
Publicado: (2018)

Advanced Urothelial Carcinoma: Overcoming Treatment Resistance through Novel Treatment Approaches
por: Bambury, Richard M., et al.
Publicado: (2013)

Mouse N-acetyltransferase type 2, the homologue of human N-acetyltransferase type 1
por: Kawamura, Akane, et al.
Publicado: (2008)

Ipilimumab induced digital vasculitis
por: Padda, Amrita, et al.
Publicado: (2018)

DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors
por: Bambury, Richard M, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_43inpvitlona1uinqd4bfvpsai